This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Infosys (INFY) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
While Infosys' (INFY) Q1 performance is likely to have benefited from the ongoing digital transformations and large deal wins, elevated expenses might have hurt the bottom line.
Top Analyst Reports for Oracle, Abbott & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Abbott Laboratories (ABT) and Chevron (CVX).
Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes
by Zacks Equity Research
Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.
LabCorp Launches At-Home Coronavirus Test Collection Kit
by Zacks Equity Research
LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.
Danaher Shares Gain 26% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Danaher (DHR), with 26% growth in shares in the past three months, benefits from healthy demand for its products and synergistic benefits from acquired assets despite the pandemic-led woes.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Zoom Video Communications, Amazon.com and NVIDIA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Zoom Video Communications, Amazon.com and NVIDIA
4 Stocks to Play the Alarming Spike in Cases of COVID-19
by Tirthankar Chakraborty
From an investment perspective, the spurt in new coronavirus cases over the July fourth weekend bodes well for certain stocks.
Medical Products Industry's Near-Term Outlook Lacks Spark
by Trina Mukherjee
AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $92.23, moving +0.64% from the previous trading session.
3 MedTech Stocks to Buy Amid Intensifying Coronavirus Fears
by Trina Mukherjee
Let's keep a watch on three stocks that have shown tremendous promise amid the pandemic.
Abbott, Tandem Diabetes Seal Deal on Diabetes Management
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.
Abbott (ABT) Stock Moves -1.02%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $88.71, moving -1.02% from the previous trading session.
Coronavirus Diagnostic Tests in High Demand: 4 Stocks in Focus
by Debanjana Dey
Amid the pandemic, these four companies with strong diagnostics testing developments might show better resilience.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $90.28 in the latest trading session, marking a -0.68% move from the prior day.
3 MedTech Stocks to Watch Amid Coronavirus Catastrophe
by Trina Mukherjee
Let's keep a watch on three stocks that have displayed strong performance amid market turmoil led by the ongoing pandemic.
Abbott's Libre 2 iCGM Gets FDA Nod to Better Manage Diabetes
by Zacks Equity Research
Abbott's (ABT) FDA-cleared FreeStyle Libre 2 iCGM is the only available system to continuously transmit glucose data with real-time alarms.
Abbott's (ABT) FreeStyle Libre Study Outcome Favorable
by Zacks Equity Research
The latest study outcome aligns with the American Diabetes Association's recommended A1c level of 7% for adults with diabetes.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $89.02, marking a +1.41% move from the previous day.
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments
Diagnostic Testing Remains Crucial in Combatting Coronavirus
by Trina Mukherjee
Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.
Danaher's (DHR) Product Offerings to Aid Amid Pandemic Scares
by Zacks Equity Research
Danaher's (DHR) risks from pandemic-related uncertainties are evident from weak sales projections for the second quarter. Demand for acute care diagnostics' related products might aid results.
Abbott Stock Down on Urgent Field Safety Notice for TactiCath
by Zacks Equity Research
Abbott (ABT) also mentions certain guidelines related to product return, reporting, and customer assistance.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $92.62 in the latest trading session, marking a -0.42% move from the prior day.